Neurotensin Hexapeptides
US5393740A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jul 28, 1992 |
| Grant date | Feb 28, 1995 |
| Priority date | — |
| Expiry date | Jul 28, 2012 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A hexapeptide represented by formula (II): EQU A-B-Pro-C-D-E (I) where A represents an L- or D- form of arginine or lysine whose N-terminal amino group is alkylated or acylated, B represents an L- or D- form of argine, lysine, or histidine, Pro represents an L- or D- form of proline, C represents an L- or D- form of tyrosine, tryptophan, or phenylalanine, D represents an L- or D- form of valine, isolencine, or leucine, and E represents an L-or D- form of valine, isolencine, or lencine, one of the hydrogen atoms of the amino group of which may be substituted a C.sub.1 to C.sub.4 alkyl group, and C-terminal carboxyl group of which is substituted with --COOR*, --CH.sub.2 OR, or --CONHR wherein R* represents a C.sub.1 to C.sub.4 alkyl group, and R represents a hydrogen atom or an C.sub.1 to C.sub.4 alkyl group. The hexapeptide or a pharmaceutically acceptable salt of the hexapeptide is useful as medical agent such as an anti-edematous agent, an anti-shock agent, an anti-thrombus agent, an anti-arteriosclerotic agent, an anti-allergic agent, a hypotensive agent, a wound healing agent, and an anti-inflammatory agent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.